Complement Pathway, Classical

• 

  Subject Areas on Research

  • A complement-resistant HeLa cell line (T638) is blocked at the step of C3 deposition. 
  • Acquired C1-inhibitor deficiency. 
  • Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q. 
  • Characterization of the hematopoietic defect in paroxysmal nocturnal hemoglobinuria. 
  • Classical complement pathway activation by antipneumococcal antibodies leads to covalent binding of C3b to antibody molecules. 
  • Complement and arthritis: another step in understanding. 
  • Complement deficiencies. 
  • Complement in the pathophysiology of human disease. 
  • Detection of complement in relation to disease. 
  • High dose intravenous immunoglobulin does not affect complement-bacteria interactions. 
  • High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. 
  • High doses of intravenous immunoglobulin do not affect the recognition phase of the classical complement pathway. 
  • IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model. 
  • Inherited deficiencies of complement and complement-related proteins. 
  • Inhibition of the complement cascade by the major secretory protein of vaccinia virus. 
  • Interaction of Neisseria gonorrhoeae with classical complement components, C1-inhibitor, and a monoclonal antibody directed against the Neisserial H.8 antigen. 
  • Interaction of desialated guinea pig erythrocytes with the classical and alternative pathways of guinea pig complement in vivo and in vitro. 
  • Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization. 
  • Isolation and characterization of a novel plasma protein which binds to activated C4 of the classical complement pathway. 
  • Modulation of FcR function by complement: subcomponent C1q enhances the phagocytosis of IgG-opsonized targets by human monocytes and culture-derived macrophages. 
  • NIH conference. Primary biliary cirrhosis and the complement system. 
  • Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway. 
  • Regulation of complement activity by vaccinia virus complement-control protein. 
  • Regulation of the B cell response to T-dependent antigens by classical pathway complement. 
  • Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes. 
  • Surfactant protein A regulates complement activation. 
  • The complement system in clinical diagnosis. 
  • The complement system in host defense and inflammation. 
  • The critical role of complement in experimental pneumococcal sepsis. 
  • The effect of bursectomy on natural xenoreactive antibodies and vascularized rat cardiac xenograft rejection in the chicken. 
  • The requirement of specific anticapsular IgG for killing of Haemophilus influenzae by the alternative pathway of complement activation.